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 1.  Introduction 
 Current cancer therapies have attracted wide attention and have 
had promising success. [ 1–3 ] However, these therapies still have 
limitations such as (1) inability to bypass biological barriers, 
(2) nontargeted delivery and passive distribution of drugs, 
(3) ineffectiveness against metastatic disease, and (4) lack of 
an effective modality for treatment moni-
toring. [ 4–7 ] Over the past 20 years, the devel-
opment of nanotechnology has provided 
some potential methods to overcome these 
challenges. An example of such a method-
ology utilizes a single nano medicine for 
the dual purpose of targeted drug delivery 
and in vivo drug monitoring. [ 8–10 ] 
 Magnetic resonance imaging (MRI) 
has become a powerful noninvasive tool 
in the clinical diagnosis of disease and in 
vivo imaging through the ability to acquire 
3D tomographic images with high spa-
tial resolution. [ 11,12 ] Contrast agents are 
an important consideration when using 
MRI; however, most clinical contrast 
agents such as gadolinium chelated dieth-
ylenetriaminopentaacetic acid (Gd-DTPA) 
are small, nontargeted compounds. As such, they sometimes 
passively distribute into the interstitial spaces of tissues and 
organs, resulting in an insuffi cient signal enhancement. With 
the development of new contrast agents, magnetic nanomate-
rials have emerged as ideal agents for disease diagnosis and 
therapy because they can also be used as magnetic-fi eld-guided 
drug delivery vehicles. [ 13,14 ] 
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 Iron oxide nanoparticles (IONs) such as Fe 3 O 4 serve as good 
contrast agents ( T 2 -weighted) due to their biocompatibility and 
magnetic properties. [ 15–17 ] However,  T 2 -weighted dark signals 
gained with IONs are easily disturbed by signals from calci-
fi cation, bleeding, or metal deposits, and these artifacts can 
impact background imaging. [ 18–20 ] As a result, the development 
of multifunctional imaging agents (such as  T 1 – T 2 dual-modal 
contrast agent) for obtaining more accurate diagnostic images 
is needed. [ 21 ] In order to address this issue, recent efforts have 
been made to introduce appropriate atoms (such as lanthanide 
ions) into the ION to obtain  T 1 -contrast enhancement because 
lanthanide ions possess more unpaired electrons in their f-elec-
tronic orbit. [ 22–25 ] However, doped particles which possess these 
physical and chemical characteristics have not been found to be 
signifi cantly different from the parent, undoped ION. [ 26 ] Thus, 
alternative doping ratios and atoms need to be further investi-
gated to acquire high effi cient  T 1 – T 2 dual-modal contrast agents 
for MRI. 
 Another key objective in the development of IONs is to pro-
duce them to serve as targeted drug delivery vehicles, specifi -
cally to enhance therapeutic effi ciency of cancer drugs. Over 
the past decade, many nanocarriers, including organic, inor-
ganic, and hybrid ones, have been developed as targeted drug 
delivery systems for transporting therapeutic agents to disease 
sites. [ 7,27,28 ] The intrinsic instable nature of organic systems 
precludes on their clinical use. In contrast, IONs have clinical 
promise because of their capacity to simultaneously serve dual 
roles: as targeted vehicles for controlled release of drugs and as 
imaging probes for MRI. [ 29 ] 
 In this work, we designed a multifunctional gadolinium-
doped iron oxide nanoparticle (GION) which had highly specifi c 
imaging properties and folic acid (FA) receptor specifi city for 
targeted drug delivery. Doxorubicin (DOX, a clinical anticancer 
drug) was chosen as the model drug and loaded in GION. The 
results showed that DOX was released from this FA–GION–
DOX system only after receptor-mediated internalization into 
the acidic environment of endosomes and lysosomes. Systemic 
delivery of FA–GION–DOX signifi cantly inhibited the growth 
of tumors and showed good MR enhancement in a human cer-
vical cancer xenograft model. 
 2.  Results and Discussion 
 2.1.  Synthesis and Characterization of GION 
 As shown in step 1 of  Scheme  1 , GION was fabricated by 
thermal decomposition of iron acetylacetonate and gadolinium 
acetylacetonate complexes in polyethylene glycol and ethylene 
glycol, which contained polyethylenimine (PEI) as a surfactant. 
Transmission electron microscopy (TEM) images showed that 
the as-synthesized GION was nearly monodisperse nanocrystal 
( Figure  1 a–c). In addition, Fe/Gd ratio in the GIONs could be 
adjusted by controlling the molar ratio of the precursors, and the 
content of Fe and Gd elements was determined by inductively 
coupled plasma mass spectrometry (ICP-MS). Interestingly, we 
found that the size of GION gradually decreased with increasing 
amounts of Gd atoms (Figure S1, Supporting Information). 
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 Scheme 1.  Schematic illustration of the synthetic procedure for FA–GION–DOX.
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 From the high resolution TEM (HRTEM) images of a 
single GION nanosphere (insets located in the bottom right of 
Figure  1 d–f), it could be seen that the nanosphere was com-
posed of lots of tiny nanocrystals with almost same sizes of 
5 nm, indicating this nanosphere is a type of superparticle. [ 30–32 ] 
As shown in Figure  1 d, the distance between two adjacent 
planes of Fe 3 O 4 nanocrystal was measured to be 0.256 nm, cor-
responding to the (311) plane. However, once Gd ions were 
doped into crystal lattice, the distance between these adjacent 
planes began to increase gradually (Figure  1 e,f). The energy-
dispersive X-ray element mapping and face scanning analysis 
indicated that the distribution of Gd and Fe elements in GION 
was homogeneous (Figure  1 g,h and Figures S2–S3, Supporting 
Information). 
 X-ray diffraction (XRD) was used to confi rm the crystalline 
structure of GION, and it exhibited obvious diffraction peaks 
assigned to the spinel structure of magnetite, which were dif-
ferent from the Gd 2 O 3 simply embedded in ION because in 
that case obvious diffraction peaks of cubic Gd 2 O 3 would cer-
tainly appear. In addition, compared to Fe 3 O 4 , the diffraction 
peaks of GION shift to the left, indicating that the interplanar 
spacing distance of spinelle enlarged because of doping Gd 
ions. On the other hand, in  Figure  2 a, lattice distortion of 
GION increased with the content of the Gd element in ION, 
which could be explained that the larger size of the Gd atom 
occupied the site of the Fe atom. [ 33,34 ] X-ray photoelectron spec-
troscopy (XPS) analysis confi rmed the presence of Fe and Gd, 
O, C, and N in the GION (Figure  2 b). Further analysis of the 
Fe2p peaks in the XPS spectrum of GION showed the Fe2p1/2 
and Fe2p3/2 peaks at 711.4 and 724.6 eV (Figure  2 c), respec-
tively, thus confi rming the presence of Fe(III). The presence 
of Gd(III) was also confi rmed by the Gd4p peaks at 142.6 and 
157.9 eV. 
 2.2.  Magnetic Property and MRI Performance 
 Field-dependent magnetization ( M / H ) curves of Fe 3 O 4 
showed saturation magnetization moments ( M s) were about 
79.5 emu g −1 at 300 K ( Figure  3 a). However, the saturated mag-
netization of GION with different Gd/Fe ratios was much lower 
than that of Fe 3 O 4 at 300 K (Figure  3 a). Zero-fi eld cooling (ZFC) 
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 Figure 1.  TEM and HRTEM images of a,d) Fe 3 O 4 , b,e) Gd 0.06 Fe 2.94 O 4 , and c,f) Gd 0.6 Fe 2.4 O 4 . Scanning TEM images in g,l) bright fi eld and h,m) dark 
fi eld, and the corresponding element area mappings of i–k,n–p) Gd 0.6 Fe 2.4 O 4 .
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and fi eld cooling (FC) measurements gave the blocking tem-
perature ( T B ) of GION under an applied magnetic fi eld 100 Oe 
(Figure  3 b–e). It could be seen that blocking temperature 
decreased with increasing Gd content in GION, indicating that 
superparamagnetism of GION could be adjusted by control-
ling Fe/Gd ratio in GION. However, once Gd/Fe ratio exceeded 
30%, magnetic property of GION was similar to cubic Gd 2 O 3 
(Figure  3 a,f), indicating that the Gd–O–Fe bond changed to 
a Gd–O–Gd bond due to excess Gd atoms existing in GION. 
The superparamagnetism of GION ensures the spin order of 
Gd(III) in the inner location of GION has the same direction 
under an external magnetic fi eld. As a result, a local magnetic 
fi eld could be formed, which obviously increases the relaxivity 
of Gd ions and magnetic fi eld inhomogeneity of the  T 2 con-
trast agent, and then further enhances the  T 1 or  T 2 contrast 
effect. [ 35 ] Therefore, we hypothesized that suitable Gd/Fe ratio 
in GIONs could show excellent magnetic property, resulting in 
good  T 1 – T 2 dual-modal ability. On the basis of the above mag-
netic results, it can be envisioned that Gd 0.6 Fe 2.4 O 4 might have 
great potential in  T 1 and  T 2 relaxation enhancements because it 
showed good superparamagnetism, and suitable saturation  M s 
and Gd content. 
 To confi rm the above hypothesis, the contrast enhancement 
ability of GIONs with different Gd/Fe ratios was investigated 
using a 9.4 T MRI scanner. Longitudinal ( r 1 ) and transverse 
relaxivity ( r 2 ) values of GION were calculated through the ratio 
of 1/ T i ( i = 1 and 2) to metal ions concentration for evaluating 
contrast agent performance. With increased Gd contents in 
GION, we observed increases in both  r 1 and  r 2 values. GIONs 
with 1/4 of Gd/Fe ratio (Gd 0.6 Fe 2.4 O 4 ) displayed the highest  r 1 
and  r 2 values at 7.87 × 10 −3 and 182.7 × 10 −3  M −1 s −1 , respec-
tively, which were both much higher than those of the same 
size of Gd 2 O 3 and Fe 3 O 4 . [ 36,37 ] However, once the ratio of Gd/
Fe exceeded 1/4 to 1/2, the  r 1 and  r 2 values of GION decreased 
rapidly to 3.02 × 10 −3 M −1 s −1 and 1.6 × 10 −3  M −1 s −1 , respectively. 
The  r 1 and  r 2 values of different Gd/Fe ratios were also sum-
marized in Figure S4 (Supporting Information), indicating that 
GIONs with 1/4 of Gd/Fe ratio possessed the best MRI perfor-
mance. Therefore, optimal Gd/Fe ratio in GION could be con-
fi rmed at 1/4, indicating that GION with 1/4 of Gd/Fe ratio can 
act as both excellent negative and positive contrast agents by a 
synergistically enhanced contrast effects. In alignment with our 
hypothesis, these results demonstrated the synergistic enhance-
ment of  r 1 and  r 2 relaxivity in GION. 
 2.3.  Drug Loading and Release Behavior 
 It has been established that the microenvironment of tumor 
cells is weakly acidity, such as tumor and infl ammatory tis-
sues (pH 6.5), corresponding endosomes (pH 5.5–6.0), and 
lysosomes (pH 4.5–5.0). [ 38,39 ] Therefore, it will undoubtedly 
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 Figure 2.  a) XRD patterns of Fe 3 O 4 , Gd 0.06 Fe 2.96 O 4 , and Gd 0.6 Fe 2.4 O 4 ; b) full XPS spectra of Gd 0.06 Fe 2.96 O 4 and Gd 0.6 Fe 2.4 O 4 ; c) XPS Fe2p peaks and 
d) Gd4d peaks of Gd 0.6 Fe 2.4 O 4 .
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help to kill tumor cells much more effectively if GION loaded 
with drugs possess pH-dependent release behavior. As shown 
in Scheme  1 , DOX was loaded onto GION by a pH-sensitive 
hydrazone bond, and Fourier transform infrared (FTIR) spectra 
were used to monitor the modifi cation process (Figure S5, 
Supporting Information). The peak at 586 cm −1 in all curves 
was attributed to the typical Fe–O stretching vibration. In the 
curve of GION, the peaks at 1075, 1634, 2938, and 2853 cm −1 
were respectively ascribed to C–N stretching vibration, N–H 
bending vibration, and C–H stretching vibration, indi-
cating that GION contained plenty of PEI chains. After the 
hydrazide bonds were formed on the GION, new peaks at 
1648 and 3314 cm −1 appeared in the GION–hydrazide curve, 
which was assigned to the characteristic bond of linkage in 
–CH 2 CH 2 CONHNH 2 . In addition, in the curve of GION–DOX, 
the characteristic peaks at 1540, 1460, and 1410 cm −1 corre-
sponded to the skeleton vibration of the benzene ring in DOX, 
indicating that the DOX was successfully conjugated to GION. 
It was noteworthy that the peak at 1715 cm −1 belonging to 
C O stretching vibration of free DOX was absent, thus indi-
cating that DOX was covalently bound with GION. Interest-
ingly, in the curve of FA–GION–DOX, the characteristic peak of 
C O stretching vibration reappeared at 1687 cm −1 , indicating 
FA was linked to GION–DOX by amide bond. The loading 
capacity of DOX conjugated into GION was calculated to be 
≈9.6 wt% by UV–vis analysis. 
 Subsequently, we investigated the release behavior of DOX 
from GION–DOX using UV–vis spectra (490 nm) in phosphate 
buffers at neutral and weakly acidic pH. The release curves of 
DOX were shown in  Figure  4 a. The release amount of DOX 
molecules was negligible for GION–DOX at pH 7.4, indicating 
that the hydrazone bond linking the GION and DOX was very 
stable at neutral condition. However, a marked increase in 
DOX concentration of the supernatant was observed at pH 5.5, 
indicating that DOX molecules were released effi ciently from 
GION–DOX under the weakly acidic conditions. Additionally, 
the release rate of DOX was faster with decreasing pH value, 
displaying typical pH-dependent release behavior. 
 2.4.  Cell Viability, Uptake, and Localization 
 In order to evaluate the application of GION for cancer treat-
ment and diagnosis, HeLa cells incubated with free DOX, 
GION, GION–DOX, and FA–GION–DOX were assessed 
through a Cell Counting Kit-8 (CCK-8) assay. GIONs did not 
result in a signifi cant decrease in cell viability at a wide range 
of concentrations. This was an indication that the toxicity of 
GIONs was negligible (Figure  4 d). However, GION–DOX 
exhibited a dose-dependent cytotoxic effect, which was similar 
to that observed with equivalent doses of free DOX when the 
concentration of DOX was above 12 µg mL −1 (Figure  4 e). This 
is crucial that GION–DOX showed low cytotoxicity when the 
concentration of DOX was less than 12 µg mL −1 . This could 
be explained that low dose of GION–DOX cannot be inter-
nalized by HeLa cells, resulting in the low release amount of 
DOX. Compared with GION–DOX, FA–GION–DOX displayed 
a signifi cant reduction in cell viability after a 24 h incubation 
period, indicating that folic acid was benefi cial for the uptake of 
FA–GION–DOX on HeLa cells and effect of DOX on the cancer 
cells. Flow cytometry results showed obvious lower cellular 
uptake of GION–DOX and FA–GION–DOX in the presence of 
folic acid than that of FA–GION–DOX within 24 h of incuba-
tion (Figure  4 f). 
 To further investigate the effects of nanomaterials on intracel-
lular localization of DOX, their intracellular localization in the 
living cells was observed by confocal microscopy ( Figure  5 ). For 
HeLa cells treated with free DOX, red fl uorescence was visible 
inside cells, suggesting fast diffusion and internalization after 
4 h of incubation. Meanwhile, the GION–DOX exhibits weak 
green fl uorescence in cytomembrane and negligible red fl uores-
cence in cytoplasm, which suggested that GION–DOX cannot 
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 Figure 3.  a) Hysteresis loops of samples at 300 K; the temperature dependence of ZFC and FC magnetization curves for b) Fe 3 O 4 , c) Gd 0.06 Fe 2.94 O 4 , 
d) Gd 0.3 Fe 2.7 O 4 , e) Gd 0.6 Fe 2.4 O 4 , and f) GdFe 2 O 4 .
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be internalized by HeLa cells, resulting in no DOX release 
from GION–DOX. However, all of the HeLa cells showed a 
bright fl uorescence in green and red light, which indicated 
that FA–GION–DOX exhibited effi cient intracellular delivery in 
tumor cells with colocalization in lysosome and entering into 
the nucleus. These results confi rmed that FA–GION–DOX can 
effectively deliver the drugs into living cells and possess a pH-
dependent drug release profi le within cancer cells. 
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 Figure 5.  Confocal laser scanning microscopy (CLSM) observations of HeLa cells incubated with A) DOX, B) FITC labeled GION–DOX, and FA–
GION–DOX in the C) absence and D) presence of 5 × 10 −3  M free folic acid. For each panel, the images from left to right show cell nuclei stained by 
DAPI (blue; DAPI: 4′,6-diamidino-2-phenylindole), FITC fl uorescence in cells (green), DOX fl uorescence in cells (red), bright fi eld, and the merged one 
of the left four images. All images share the same scale bar.
 Figure 4.  a) Release behavior of FA–GION–DOX under different pH conditions; b) the transverse relaxation rate of samples through the ratio of 1/ T 2 to 
Fe concentration; c) the longitudinal relaxation rate of samples through the ratio of 1/ T 1 to Gd concentration; d) CCK-8 assay for HeLa cells viabilities 
after incubation with different concentrations of FA–GION; e) viabilities of HeLa cells treated with free DOX, GION–DOX, FA–GION–DOX at different 
concentrations for 12 h; f) fl ow cytometry analysis of HeLa cells incubated with FITC labeled different samples for 2 h. The red line represents the 
negative control sample.
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 2.5.  Antitumor Effect in a Subcutaneous Human Cervical Cancer 
Xenograft Model 
 The in vivo therapeutic effi cacy of free DOX, GION–DOX, and 
FA–GION–DOX for cervical cancer was evaluated in BALB/c 
nude mice ( Figure  6 a). The tumor growth rates of mice treated 
with physiological saline (control) showed rapid tumor growth, 
indicating that physiological saline alone had no effect on 
tumor growth. In contrast, the groups injected with the free 
DOX or GION–DOX had greatly delayed and inhibited tumor 
growth. After 38 d, free DOX and GION–DOX suppressed 
tumor volumes by 62.5% and 37.5%, respectively, compared 
with the control group. However, tumor volume appeared 
as explosive growth for injecting free DOX or GION–DOX to 
mice, which was ascribed to resistant drug of cancer cells. [ 40,41 ] 
In contrast, FA–GION–DOX displayed a signifi cant inhibitory 
effect in tumor size, which may be mainly due to the sustained 
DOX release in vivo in the tumor tissue after particle accumula-
tion via targeting effect of folic acid. Images of Figure  6 b were 
consistent with Figure  6 a, showing that FA–GION–DOX pos-
sessed a stronger inhibitory effect on tumor growth. 
 We further investigated the biodistribution of GION–DOX 
and FA–GION–DOX in vivo. After injection by caudal vein 
about 30 min, the mice were sacrifi ced and the tumors and 
major organs (e.g., lymph, liver, kidney, and spleen) were col-
lected. The samples were then evaluated through measurement 
of Gd 3+ content using ICP-MS, and the data are presented as the 
accumulation of GION per mass unit of an organ (Figure  6 c). 
The amount of FA–GION–DOX in the tumor was 3-fold higher 
than that of GION–DOX, which suggested that folic acid dis-
played good targeting in vivo. 
 In addition, the biodistribution data showed that consider-
able amounts of GIONs and FA–GIONs accumulated in the 
liver and spleen due to the reticuloendothelial system. We 
suppose that FA–GIONs tend to accumulate in tissues with a 
high density of folate receptors and could be excreted from the 
body mainly through hepatobiliary clearance. [ 42 ] The data sug-
gest that FA–GION–DOX can selectively recognize the tumor 
tissues among different tissues as a result of the hydrolyza-
tion of hydrazone bonds induced by the acidic tumor micro-
environment. Compared to traditional chemotherapy, nano-
particle-mediated drug delivery reduces the risks associated 
with systemic distribution of the drug mitigating unwanted 
side effects. [ 43 ] Side effects of free DOX, GION–DOX, and 
FA–GION–DOX were evaluated through changes in weight of 
the mice. As shown in Figure  6 d, the weight of mice did not 
increase with injection of free DOX, suggesting that DOX 
infl uenced the normal growth of mice as a result of damage 
caused by free DOX on normal tissues. [ 44 ] However, the weight 
of mice has the normal growth from 18 to 25 g by injecting 
GION–DOX. Importantly, the treatment of FA–GION–DOX 
caused a signifi cant increase in the weight of mice because 
the cancer was well controlled. These results suggest that 
FA–GION–DOX can reduce the side effects of DOX chemo-
therapy and enhance the survival rate of cancer patients. 
 Hematoxylin and eosin (H&E) staining results of hypo-
dermatic tumors ( Figure  7 ) showed numerous necrotic areas 
and highly malignant hyperchromatin tumor cells in the 
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 Figure 6.  a) Tumor volume changes of saline-treated mice compared to mice treated with DOX, GION–DOX, and FA–GION–DOX over 2 months; 
b) photos of mice treated with different samples; c) in vivo biodistribution of GION–DOX and FA–GION–DOX in nude mice of bearing cancer after 
the intravenous injection (GION, 300 µg); d) weight changes of mice treated with different samples.
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slides. Nuclear atypia could also be observed inside the cells of 
tumors. Tumor cell density and quantity of atypical nuclei were 
estimated approximately by experienced pathologists under 
optical microscope with 200× magnifi cation. The pathologists 
selected the boundary and core tissues of tumors in every 
slides, respectively, and gave analysis as follows: (1) necrotic 
areas in slides of experimental groups (FA–GION–DOX) were 
more than control groups; (2) the density of hyperchromatin 
tumor cells of experimental group was smaller than that of 
control group while the quantity of atypical nuclei was larger 
than that of control group. 
 2.6.  Monitoring Targeted Delivery of FA–GION–DOX by 
Noninvasive MRI 
 To observe if the systemic delivery of FA–GION–DOX leads 
to the specifi c accumulation of nanoparticles in tumors, the 
tumor-bearing mice were observed by MRI, following the FA–
GION–DOX treatment.  T 1 and  T 2 images at transverse planes 
of region of interest tumors were acquired at preinjection and 
15, 30, 60, and 120 min postinjection of FA–GION–DOX or 
GION–DOX with a dose of 2.0 mg kg −1 mouse body weight 
through tail vein. We found that  T 2 -weighted images of tumor 
in mice treated with FA–GION–DOX appeared signifi cantly 
darken at 30 min, which suggested that FA–GION–DOX 
nanoparticles were accumulated in tumor area ( Figure  8 a). 
Moreover, the MRI signal intensity of  T 2 -weighted images 
decreased 33% after the tumors of mice were injected by 
FA–GION–DOX for 30 min, compared to the signal level 
obtained before treatment (Figure  8 b). Following this, the 
MRI signal change dropped at 120 min may be due to excre-
tion of FA–GION–DOX by metabolism pathway. However, 
 T 2 -weighted MRI showed no signifi cant signal decrease in 
tumors of the mice treated with nontargeted GION–DOX. 
Correspondingly,  T 1 signal changes were demonstrated at 
the same time and showed similar to  T 2 signal results. As 
shown in Figure  8 c,  T 1 -weighted MR images exhibited a sig-
nifi cantly brighter signal in the tumor of mouse with FA–
GION–DOX at 15 min postinjection. The analysis of MRI 
signal changes in the tumor region indicated that the big-
gest intensity change, of ≈74% in  T 1 imaging, occurred at 
 Figure 7.  1) Photomicrographs of HeLa cell xenograft tumors with H&E staining. 2) Hyperchromatin cell density of tumor tissues in boundary: 
B > E > H > K. (3) Necrotic areas of tumor tissues in core: C < F < I < L.
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60 min postinjection (Figure  8 d). However, tumors treated 
with GION–DOX displayed a weak brighter area in  T 1 -
weighted images and only 31% enhancement in MRI signal 
change. These results suggest that FA–GION–DOX has 
potential to serve as a targeted  T 1 – T 2 dual-model MRI contrast 
agent for tumor imaging, which may be helpful for accurate 
diagnosis and treatment of cancer. 
 3.  Conclusion 
 In summary, we introduced an effi cient strategy to develop 
a high-performance MRI contrast agent and targeted drug 
delivery system, FA–GION–DOX, via modifying surface struc-
ture and nanobiointerface. GION displayed a signifi cant con-
trast enhancement in  T 1 and  T 2 imaging, which could be 
attributed to the synergetic effect of Gd and Fe atoms. Mean-
while, targeted FA–GION–DOX resulted in pH-dependent con-
trolled release of the therapeutic agent. This FA–GION–DOX 
nanosystem not only enables intracellular drug release, but also 
allows the detection of the nanodrug accumulation in tumors 
by  T 1 – T 2 dual-model imaging. Our results demonstrated that 
systemic delivery of FA–GION–DOX signifi cantly inhibited 
tumor growth in a human cervical cancer xenograft model. We 
further showed that targeted delivery of the FA–GION–DOX 
and the presence of the nanodrug could be detected in the 
tumor through noninvasive means, using both  T 2 -weighted and 
 T 1 -weighted MRI. Therefore, FA–GION–DOX developed in this 
study is a promising drug delivery system for the targeted and 
image-guided therapy of cervical cancer. 
 4.  Experimental Section 
 Materials : All chemical reagents were used as received without further 
purifi cation. Ethylene glycol, triethanolamine (TEA), dimethylsulfoxide, 
polyethylene glycol ( M w : 400) were purchased from Sinopharm Co. 
(Shanghai, China). DOX, PEI, N-hydroxysuccinimide (NHS), N-ethyl-N′-
(3-dimethylaminopropyl) carbodiimide (EDC), Gd(acac) 3 , and Fe(acac) 3 
were received from Aladdin Co. (Shanghai, China). Hoechst 33342, 
trypan blue, propidium iodide were purchased from Sigma-Aldrich. Co. 
(USA). The CCK-8 was obtained from Dojindo (Japan), and an Annexin 
V-FITC Apoptosis Detection Kit was purchased from BD Biosciences 
(San Jose, CA, USA). All other analytical grade chemicals were obtained 
from Sinopharm Group Chemical Reagent Co., Ltd (Shanghai, China). 
 Synthesis of GION : The various ratios of iron acetylacetonate and 
gadolinium acetylacetonate complexes were dissolved in a mixed 
solution of ethylene glycol (15 mL) and polyethylene glycol (35 mL) for 
30 min at 80 °C. Next, PEI was added in the solution to form a brown 
turbid solution for 30 min. Afterward, TEA (3 mL) was added under 
stirring to form a homogeneous and transparent solution. This solution 
was then transferred to an autoclave and kept at 230 °C for 2 d. Finally, 
the black product was collected and washed at least three times with 
distilled water and alcohol. 
 Preparation of FA – GION – DOX : (1) GIONs contained with amino 
groups were dispersed in distilled DMF for 2 h at 60 °C. Subsequently, 
triethylamine was added in the resulting solution under nitrogen. 
After 30 min, DMF containing acrylic ester was added to the above 
solution under nitrogen, and allowed to react for 12 h to form GION–
vinyl. Subsequently, hydrazine was further added in the mixed solution 
 Figure 8.  Delivery of FA–GION–DOX in tumor by  T 1 – T 2 dual-modal MRI monitoring. a)  T 2 - and c)  T 1 -weighted MR images (9.4 T) of mice acquired at 
preinjection and 15, 30, and 60 min postinjection of FA–GION–DOX and GION–DOX with a dose of 2.0 mg (GION) kg −1 (mouse body weight). MRI 
signal changes in tumor of c)  T 2 - and d)  T 1 -weighted images at transverse planes ( n = 3, data represent mean ± standard deviation), showing that 
maximal signal changes in tumor were achieved at postinjection about 30 min. Tumor marked by a white arrow.
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contained GION–vinyl for 4 h. After that, the active ester of folic acid 
prepared as reported previously [ 45 ] was added into the resulting solution 
for 6 h, and then folic acid could link to GION-hydrazine through 
conjugating the rest amine groups on the surface of GION. The product 
(FA–GION–hydrazine) was collected by external magnets and washed 
using ethanol. (2) DOX was conjugated to FA–GION–hydrazine through 
formation of hydrazone bonds. Commonly, DOX and acetic acid were 
added to methanol solution of GION–hydrazine and reacted for 2 d 
under nitrogen condition at room temperature. The product (FA–GION–
DOX) was collected by external magnets and washed with ethanol until 
the supernatant was clear, with no color being visibly detectable. 
 Release Kinetics of FA – GION – DOX : FA–GION–DOX (10 mg) was 
fi rst dispersed into simulated body fl uid (pH 7.4, 10 mL). Then, these 
solutions were poured into dialysis bags. While stirring, the dialysis bags 
were rapidly immersed in the same buffer (100 mL) at room temperature 
for 20 h. Subsequently, the pH values of medium were adjusted to 5.5, 
4.5, or 3.0 by adding HCl solution (0.05  M ). Medium was collected at 
defi ned time intervals and the amount of released DOX was determined 
using a UV–vis spectrophotometer at a wavelength of 488 nm. 
 MR Experiment : The capability of nanoplatforms to infl uence  T 1 or 
 T 2 relaxation time was studied using a 9.4 T, 8.9 cm wide bore, actively 
screened, transverse bore MR spectrometer (Bruker Biospoin GmbH, 
Germany). The longitudinal ( T 1 ) and transverse ( T 2 ) relaxation rates were 
measured using the inversion recovery method and a multi-echo spin 
echo sequence, respectively. The relaxivities ( r 1 and  r 2 ) were determined 
by a linear fi t of the inverse relaxation time as a function of metal ions 
concentration, which was determined using ICP-MS (ICP6300, Thermo 
Fisher Scientifi c Co., USA). 
 Cell Culture and Cytotoxicity Assay : HeLa cells were plated into 96-well 
plates at 1 × 10 4 cells per well and maintained in dulbecco’s modifi ed 
eagle medium (DMEM) supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin at 37 °C in a humidifi ed atmosphere of 5% 
CO 2 . After being cultured for 24 h, HeLa cells were treated with various 
concentrations of DOX, GION–DOX, and FA–GION–DOX, and allowed 
to further incubate for an additional 24 h. In addition, HeLa cells were 
treated with different concentrations of GION for 48 h. After incubation 
with various samples, the culture media were removed and cells were 
washed with phosphate buffer solution (PBS). The number of viable 
cells was determined using a CCK-8 (BestBio, China). Absorbance was 
measured at 450 nm using a microplate reader (ChroMate 4300, USA). 
All tests were carried out at least in triplicate. 
 Fluorescein isothiocyanate (FITC) Accumulation Assay : FITC labeled 
GION, FA–GION were fabricated by previously described methods. HeLa 
cells seeded in 60 mm plates (5 × 10 5 cells per dish) were treated with 
exogenous free folic acid (5 × 10 – 3 M) for 2 h at 37 °C followed by FITC–
FA–GION (40 µg mL −1 ) for 4 h. HeLa cells were also incubated with 
GION–FITC or FA–GION–FITC at the same concentration (40 µg mL −1 ). 
After 4 h, trypan blue (0.4%, 1 mL) was used to quench the extracellular 
fl uorescence for 2 min. Cells were next trypsinized, washed three times 
with ice-cold PBS, resuspended in PBS (500 µL), and measured by fl ow 
cytometry (BD FACScan fl ow cytometer, BD Biosciences). 
 Confocal Microscopy : HeLa cells were seeded on 15 mm glass 
coverslips placed in 12-well plates (8 × 10 4 cells per well) and incubated 
with exogenous free folic acid (5 × 10 –3 M) and after 2 h the cells were 
further incubated with FA–GION–FITC (40 µg mL −1 ) for 1, 2, and 4 h. 
Additionally, HeLa cells were also incubated with FITC–GION or 
FITC–FA–GION at the same concentration for 1, 2, and 4 h, followed 
by nuclei staining using the Hoechst Dye (Hoechst 33342). Cells 
were washed three times using PBS and fi xed in freshly prepared 4% 
paraformaldehyde. Slides were coverslipped and visualized using 
confocal microscope (Zeiss LSM710 NLO, Germany). 
 Human Cervical Tumor Xenograft Mouse Model : The cervical cancer 
model was established through direct subcutaneous injection of 
5 × 10 7 HeLa cells into the left axilla of nude mice. Three to four weeks 
following injection of cells, cervical tumors of 100 mm 3 in volume were 
apparent. The mice used for the experiment were treated in accordance 
with the Ethics Committee Guidelines in University of Science and 
Technology of China. Animals were randomized into four experimental 
groups of fi ve or six mice as follows: control, free DOX, nontargeted 
GION–DOX, and FA–GION–DOX. The mice were treated via tail vein 
injections at 4 d intervals. On each treatment d, all groups except for 
the control group were administered an equivalent dose of 2 mg kg −1 
of body weight. Control mice were injected saline buffer. The animal 
study was performed three times under the same conditions, and 
the results of three separate experiments were combined to analyze 
values. The volume ( V ) of tumor was calculated as  V = a ×  b 2 /2, where 
“ a ” and “ b ” were the longest and shortest diameters of the tumor, 
respectively. The body weights of mice were measured and recorded 
twice a week. 
 Biodistribution of FA – GION – DOX In Vivo : The biodistribution 
analysis was performed 30 min after the injection of the GION–DOX 
and FA–GION–DOX (2 mg kg −1 ). The dissected organs were weighed, 
homogenized, and then treated with scintillation mixtures. A volume 
of 60% nitric acid was added to each sample and the tissues were 
placed on water bath for 24 h at 60 °C, after which the solutions were 
centrifuged at 13 000 rpm for 10 min and the supernatant was collected 
and then subjected to ICP-MS. The GION–DOX and FA–GION–DOX 
distribution in different organs was calculated as the percentage of the 
injected dose per gram of tissue. 
 Pathological Analysis of Tumor Tissue : The tumor tissues were 
sectioned into two halves and measured. One half was used for 
quantitative analysis. The other half was fi xed in 10% buffered formalin, 
and embedded in paraffi n for histological analysis using H&E staining. 
Tumor cell density, tumor necrosis, mitotic fi gure count, and nuclear 
atypia were evaluated with light microscopy using 400× magnifi cation. 
This analysis was semiquantifi ed by experienced pathologists in a 
double blind manner. [ 46,47 ] 
 In Vivo MRI : HeLa cells (1.0 × 10 7 cells) were subcutaneously 
transplanted into BALB/c male nude mice. When the tumors grew to 
≈3 mm 3 in volume, GION–DOX and FA–GION–DOX (2 mg kg −1 ) were 
intravenously injected into the cervical-cancer-bearing mice.  T 1 -weighted 
images of the mice were acquired using a Litz coil (diameter 100 mm 
and length 85 mm) on a 9.4 T MRI scanner (Bruker Biospoin GmbH, 
Germany). The imaging parameters were as follows: fast spin echo, TR 
400.0 ms, TE 10.0 ms, and slice thickness 2.0 mm. 
 Characterization : The morphologies and element mapping of samples 
were observed on a TEM (JEM-ARM200F, JEOL Co., Japan). The structure 
and reaction were monitored using an FTIR spectrometer (Nicolet Co., 
USA). Particle size distribution measurements were conducted on a 
dynamic light scattering detector (Malvern, UK). 
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